Drug Trial Radar · NCT01009190
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Last checked: Nov 19, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Feb 2010
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- pharmaand GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors
Conditions
- Advanced Solid Tumors
Interventions
PF-01367338Drug
Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
CarboplatinDrug
Standard doses of intravenous Carboplatin administered every 3 weeks
PF-01367338Drug
RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
CarboplatinDrug
Standard doses of intravenous Carboplatin administered every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of escalating doses of PF-01367338 in combination with chemotherapy (as defined by first-cycle DLTs)Time frame: 18 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Belfast City Hospital
Belfast, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Kings College London
London, United Kingdom
Sir Bobby Robson Cancer Trials Research Centre
Newcastle upon Tyne, United Kingdom
Churchill Hospital
Oxford, Oxfordshire, United Kingdom
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.